Matthew Biegler
Stock Analyst at Oppenheimer
(1.10)
# 3,617
Out of 4,876 analysts
79
Total ratings
31.88%
Success rate
-14.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics | Maintains: Outperform | $10 → $9 | $1.20 | +650.00% | 2 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.18 | +662.71% | 2 | May 14, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $25 → $22 | $4.62 | +376.19% | 6 | May 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $10.31 | +16.39% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $8 | $1.06 | +654.72% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $7.54 | +496.82% | 4 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $110.67 | +3.91% | 1 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $21.37 | +148.01% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $9.10 | +262.64% | 6 | Sep 19, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Outperform | $20 | $1.18 | +1,594.92% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.30 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $128.11 | -2.43% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $10.68 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.10 | +97.18% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $7.90 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.04 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $6.47 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.68 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.85 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $5.45 | +6,505.50% | 1 | Nov 30, 2022 |
Acrivon Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.20
Upside: +650.00%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.18
Upside: +662.71%
Olema Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $4.62
Upside: +376.19%
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $10.31
Upside: +16.39%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $8
Current: $1.06
Upside: +654.72%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $7.54
Upside: +496.82%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $110.67
Upside: +3.91%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $21.37
Upside: +148.01%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $9.10
Upside: +262.64%
Zentalis Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.18
Upside: +1,594.92%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.30
Upside: -
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $128.11
Upside: -2.43%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $10.68
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $7.10
Upside: +97.18%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $7.90
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.04
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $6.47
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.68
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.85
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $5.45
Upside: +6,505.50%